Teva Pharmaceutical Industries Ltd.
Ouvert
SecteurSoins de santé
34.18 -1.13
Résumé
Variation du prix de l'action
24h
Min
33.9
Max
35.08
Revenu | -112M 369M |
|---|---|
Ventes | -730M 4B |
P/E Moyenne du Secteur | 24.821 49.052 |
BPA | 0.53 |
Marge bénéficiaire | 9.269 |
Employés | 31,173 |
EBITDA | 245M 877M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +21.6% upside |
Capitalisation Boursière | 2.3B 39B |
|---|---|
Ouverture précédente | 35.31 |
Clôture précédente | 34.18 |
Sentiment de l'Actualité
By Acuity
50%
50%
146 / 342 Classement par Healthcare
Teva Pharmaceutical Industries Ltd. Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.